FDA Rips 'Troubling' Drug Promo In Repeat Warning Letter

Law360, New York (November 21, 2013, 4:16 PM EST) -- For the second time in three years, Kadmon Pharmaceuticals LLC has sent promotional literature with faulty information on safety and effectiveness, a "particularly troubling" repeat offense, the U.S. Food and Drug Administration said in a warning letter released Wednesday.

The FDA's admonishment concerns a "dear doctor" letter related to hepatitis C drug Ribasphere and accuses New York-based Kadmon of spotlighting the medicine's potential benefits while burying its many risks in fine print.

Kadmon's one-page letter focused almost entirely on positive attributes of Ribasphere, waiting until the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.